Pipeline

Cardiovascular Disease

Metabolic Disease

Renal Disease

Liver Diseases

CNS Disease

Other Therapeutic Areas

Product

Target

Indication

Commercial Rights

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll

RBD7007

C5

Renal Diseases*

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll
RBD7007

RBD7007, a GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM, is being developed for treatment of complement-mediated diseases. RBD7007 inhibits the expression of complement components in hepatocytes to reduce the overactivation of the complement system, achieving the effect of treating complement-related diseases, such as renal and autoimmune diseases. RBD7007 has demonstrated robust and long-duration pharmacological effects in cynomolgus monkeys. A clinical trial application for a first-in-human study has been approved by EMA.
RBD2080

C3

Renal Diseases*

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll
RBD2080

RBD2080, a GalNAc-siRNA drug based on our proprietary liver-targeting delivery technology RiboGalSTAR^TM, is being developed for treatment of complement-mediated diseases. RBD2080 inhibits the expression of complement components in hepatocytes to reduce the overactivation of the complement system, achieving the effect of treating complement-related diseases, such as renal and autoimmune diseases. A clinical trial application for a first-in-human study of RBD2080 has been approved in Australia.
RBD3103

Undisclosed

Renal Diseases

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll
SR100

MASP2

Renal Diseases

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll
SR086

CFB

Renal Diseases

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll
SR150

Undisclosed

Chronic Renal Diseases

Global

Discovery

IND-Enabling

Phase l

Phase ll

Phase lll

* RBD7007 and RBD2080 are also under investigation as a potential treatment for autoimmune diseases.